Sortase A, Heptamutant for Antibody-Drug Conjugate Development

Antibody-drug conjugate (ADC) development requires both precise control over drug-to-antibody ratios (DARs) and the ability to rapidly iterate linker and payload designs. Traditional chemical conjugation methods often produce heterogeneous mixtures, complicating downstream analytics and regulatory comparability. Enzymatic sortase-mediated transpeptidation offers a compelling alternative, utilizing Staphylococcus aureus Sortase A to recognize an LPXTG motif, cleave between the threonine and glycine residues, and ligate an N-terminal oligoglycine nucleophile. This enables site-specific attachment of payloads (such as monomethyl auristatin E (MMAE) or pyrrolobenzodiazepine (PBD) dimers) to LPETG-engineered sites on antibody heavy or light chains, yielding homogeneous ADCs with defined DARs.

However, wild-type Sortase A exhibits limited catalytic efficiency, typically requiring extended reaction times and high enzyme concentrations. TriAltus-purified Sortase A, heptamutant featuring seven targeted mutations, delivers significantly enhanced kinetics while maintaining specificity.

The Mechanism and Advantages of Sortase A, Heptamutant

Sortase A catalyzes transpeptidation through formation of a thioacyl-enzyme intermediate from the LPXTG donor, followed by nucleophilic attack from an N-terminal glycine-bearing acceptor, releasing the conjugated product and free glycine. Engineered heptamutant variants, including those with reduced calcium dependence and improved k_cat (higher turnover rate), overcome the limitations of wild-type enzyme, reducing enzyme requirements by 10-50-fold compared to literature benchmarks.

TriAltus supplies this reagent as ≥95% pure, tag-free or His-tagged protein (1 mg/mL) in a stable formulation (20 mM Tris pH 8.0, 0.5 M NaCl, 20% glycerol), with 6-month shelf life under recommended storage. This formulation supports reliable performance in antibody-drug conjugate research and site-specific conjugation workflows.

Site-Specific Payload Attachment

A DAR of 2 or 4 is commonly used for ADC, meaning each antibody carries exactly 2 or 4 cancer-killing drug molecules. To achieve this precision, scientists first genetically engineer the antibody to display LPETG tags (short amino acid sequences) at specific locations, usually in the heavy chain CH3 domain (near the antibody's "tip") or hinge region (the flexible middle section).

The Sortase A, Heptamutant enzyme then attaches payloads like Gly₅-linker-toxin constructs where the Gly₅ (five glycines) acts as a "docking handle" and the toxin (auristatins, maytansinoids, or PBD dimers) delivers the punch. This reaction completes in ~15-30 minutes at room temperature with ~90-95% yields, using modest 1:5-10 enzyme-to-substrate ratios.

By contrast, standard Sortase A enzymes need 3-16 hours for comparable results, creating a major bottleneck during payload screening.

The resulting ADCs are uniform (all molecules have identical DARs), making characterization straightforward via hydrophobic interaction chromatography-high performance liquid chromatography (HIC-HPLC) for drug distribution and liquid chromatography-mass spectrometry (LC-MS) for molecular weight confirmation. This accelerates lead selection dramatically.

From Payload Screening to Optimized Drug-Antibody Ratios

Sortase A, Heptamutant's speed accelerates the two most time-intensive phases of ADC development: early linker/payload screening and precise DAR optimization.

1. Rapid Linker/Payload Screening
Before committing to a final toxin, teams typically will test up to 10 combinations, cleavable vs. non-cleavable linkers, pharmacokinetic (PK) modulators, and analytical handles. The same LPETG-tagged antibody serves all tests:

• Azides/alkynes for click chemistry compatibility

• Polyethylene glycols (PEGs) for circulation time tuning

• Fluorescent dyes for binding/potency assays

• Valine-citrulline (val-cit) vs. non-cleavable toxin linkers

96-well screening completes in ~90 minutes per plate (vs. overnight with standard enzymes), letting you rank candidates by stability, efficacy, and manufacturability in days, not weeks.

2. Heavy Chain DAR Precision
Once leads emerge, lock in DAR-2 or DAR-4 on heavy chains (optimal for PK and tumor exposure):

• DAR-2: Single LPETG at heavy chain CH3 C-terminus → 95% yield in ~20 minutes

• DAR-4: Dual LPETG sites (CH3 + hinge) → sequential labeling without over-modification

Heavy chain focus avoids light chain scattering, ensuring consistent drug delivery. Reaction conditions scale reliably from screening to process development.

Accelerated Development Timeline

A representative workflow demonstrates efficiency:

• Day 1: Transient expression of LPETG-monoclonal antibodies (mAbs)

• Day 2: Conjugation of 3-5 payload variants (90 minutes hands-on), Protein A purification

• Day 3: LC-MS/HIC-HPLC analysis and in vitro cytotoxicity

• Week 2: In vivo pharmacokinetic data

This approach compresses timelines by 80% relative to slower enzymatic methods, accelerating progression through discovery.

Reaction Optimization and Troubleshooting

TriAltus' ultra-pure, calcium-independent Sortase A, Heptamutant powers consistent performance without CaCl₂ requirements. Key considerations include 5-10x excess nucleophile to prevent hydrolysis and LPETA motifs which often outperform LPETG for certain antibodies. Pre-formulated for stability, our enzyme delivers lot-to-lot reproducibility- just add substrates and go. Request evaluation sample.

Why TriAltus-purified Sortase A, Heptamutant Excels

Up to 10x higher activity than alternative suppliers (demonstrated through direct benchmarking) powers TriAltus' calcium-independent Sortase A, heptamutant. This high performance stems from our proprietary CLīM purification, which delivers ultra-high purity (>95%) by eliminating performance-degrading contaminants. The result? Faster reactions (minutes vs. hours), 5-10x lower enzyme requirements, and lot-to-lot consistency through ISO 13485 manufacturing, eliminating re-optimization across your entire antibody-drug conjugate (ADC) workflow.

Shop Sortase A, Heptamutant